We believe our team is uniquely positioned to source, invest in and build a scaled platform from the multitude of disparate technology-enabled, information-driven solutions to address the pain points in today’s healthcare system. In addition, the team, along with the assembled board and advisors are highly differentiated in their level of experience founding, managing and scaling platforms. The collective team has been assembled based on their ability to (1) identify viable business models for the future of healthcare (2) assess and, if necessary enhance, the operating capabilities of the target (3) leverage their knowledge and relationships throughout the healthcare and technology industries to drive improved market position and customer access.
These criteria are not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management team may deem relevant. In the event that we decide to enter into our initial business combination with a target business that does not meet the above criteria and guidelines, we will disclose that the target business does not meet the above criteria in our stockholder communications related to our initial business combination, which, as discussed in this prospectus, would be in the form of proxy materials or tender offer documents, as applicable, that we would file with the SEC. In evaluating a prospective target business, we expect to conduct an extensive due diligence review which will encompass, as applicable and among other things, meetings with incumbent management and employees, document reviews, interviews of customers and suppliers, inspections of facilities, as well as reviewing financial and other information about the target and its industry which will be made available to us.